Brief: Medincell: Phase 1 Data Of Mdc-Tjk For Schizophrenia Patients

Medincell SA

22/05/2023 09:08

May 22 (Reuters) - Medincell SA  MEDCL.PA :
    * PHASE 1 DATA OF MDC-TJK INVESTIGATIONAL LONG-ACTING
INJECTABLE
OF OLANZAPINE FOR SCHIZOPHRENIA PATIENTS, EXHIBITED FAVORABLE
CHARACTERISTICS OF AN EXTENDED-RELEASE PROFILE
    * MDC-TJK HAS POTENTIAL TO BE FIRST LONG-ACTING INJECTABLE
OF
OLANZAPINE WITH A FAVORABLE SAFETY PROFILE
    * DATA CAME FROM A 127-PARTICIPANT PHASE 1 CLINICAL STUDY
    * NO BURST OR UNCONTROLLED RISE IN OLANZAPINE PLASMA
CONCENTRATIONS FOLLOWING MDC-TJK SUBCUTANEOUS ADMINISTRATION WAS
OBSERVED
    * AT STEADY-STATE CONDITIONS OVER 28 DOSING INTERVAL,
SYSTEMIC
EXPOSURE OF MDC-TJK AT DOSES 318, 425 AND 531 MG WERE COMPARABLE
TO ORAL DAILY CORRESPONDING DOSES 10 MG, 15 MG, AND 20 MG
    * REACHING CLINICALLY RELEVANT THERAPEUTIC OLANZAPINE PLASMA
CONCENTRATIONS (≥ 10 NG/ML) WITHIN A 1 TO 2 DAY AND MAINTAINING
THEM DURING 28-DAY DOSING INTERVAL
    * RESULTS OF THIS STUDY SUPPORTED DOSE SELECTION OF MDC-TJK
IN
ONGOING PHASE 3

Source text for Eikon:  ID:nBw2JRGNva 
Further company coverage:  MEDCL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))